1. Scrip
  2. >>R&D

Dark Cloud Lifts On Sophiris Bio's Localized Prostate Cancer Injectable Topsalysin

 
• By Emily Hayes

Phase IIb study death after intratumoral injection was unrelated to study drug, San Diego-based start-up says.

Sunshine

Sophiris Bio Inc. CEO Randy Woods said a cloud has lifted over its intratumoral injection agent topsalysin now that an investigation concluded that a patient fatality in a small Phase IIb study of localized prostate cancer was due to sudden cardiac death and unlikely to be related to the study drug.

Sophiris announced the outcome of the investigation, which included an autopsy, on Aug. 29, following the report of the death...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Removal Of REMS For CAR-Ts Could Greatly Expand Their Reach

 
• By Alaric DeArment

The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

 
• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.